Figure 1: Progression-free Survival gBRCAmut Cohort




Figure 2: Progression-free Survival Non-gBRCA – HRD positive




Figure 3: Progression-free Survival Non-gBRCA overall




Figure 4: Progression-free Survival Non-gBRCA – HRD negative




Figure 5: Progression-free Survival
Combined Study Population
(2 cohorts combined-gBRCAmut and non-gBRCAmut)




Figure 6: Progression-Free Survival in the HRDpos/BRCAwt Subgroup of the Non-gBRCAmut Cohort




Figure 7: Kaplan-Meier Plot for Progression-Free Survival in the HRDpos/Somatic BRCAmut Subgroup of the Non-gBRCAmut Cohort






Figure 8: Mean Change from Baseline (±SE) for Platelets Over Time: All Patients Cohort



Note: the data are displayed weekly for Cycle 1 and then every cycle (every 4 weeks) thereafter.

Figure 9: Kaplan-Meier Plot for Progression-Free Survival in the gBRCAmut Cohort Based on IRC Assessment by Niraparib Dose Administered for the Longest Duration (Niraparib Patients in the Safety Population)






Figure 10: Kaplan-Meier Plot for Progression-Free Survival in the Non-gBRCAmut Cohort Based on IRC Assessment by Niraparib Dose Administered for the Longest Duration (Niraparib Patients in the Safety Population)

Figure 11: Secondary Endpoints in the Primary Efficacy Populations.




Figure 12A. Analysis of Progression-Free Survival in the g*BRCA*mut Cohort

(A)




Figure 12B. Analysis of Progression-Free Survival in the non-g*BRCA*mut, HRDpos Subgroup




Figure 12C. Analysis of Progression-Free Survival in the overall non-g*BRCA*mut Cohort.

(C)




Figure 13. Analysis of Chemotherapy-Free Survival Interval in gBRCA^{mut} and non-gBRCA^{mut} cohorts





Figure 14. Analysis of Time to First Subsequent Treatment in gBRCA^{mut} and non-gBRCA^{mut} cohorts







Figure 15. Analysis of Efficacy of Next-Line Treatment in pooled gBRCA^{mut} and non-gBRCA^{mut} cohorts

Figure 16. Estimated Probability of PD at 6 Months After the Last Dose of Platinum-Based Therapy






Figure 17. Number of Lines of Platinum-Based Chemotherapy in the (A) gBRCAmut and (B) non-gBRCAmut Cohorts and Total Chemotherapy in the (C) gBRCAmut and (D) non-gBRCAmut cohorts (Placebo Arm)




Figure 18. Patient-Reported Outcomes were similar for niraparib and placebo